Multiple Sclerosis Research Reagents

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system, affecting over 2.8 million people worldwide. Pathogenesis involves T cell and B cell-mediated attack on myelin sheaths, oligodendrocyte damage, and progressive axonal degeneration. Anti-CD20 B cell depletion therapies (ocrelizumab, ofatumumab) and BTK inhibitors represent the current therapeutic frontier.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Multiple Sclerosis Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key multiple sclerosis research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

CD20 (MS20) — CD20 is the therapeutic target for B cell-depleting MS therapies (ocrelizumab, ofatumumab, rituximab). Research-grade anti-CD20 antibodies and recombinant CD20 proteins support B cell depletion mechanism studies, bioassay development, and ADA/PK assay reagent generation.
→ Browse CD20 antibodies & proteins

MOG (Myelin Oligodendrocyte Glycoprotein) — Anti-MOG antibodies define MOG antibody-associated disease (MOGAD), an important differential diagnosis from MS. Recombinant MOG proteins and anti-MOG antibodies support serological assay development and EAE (experimental autoimmune encephalomyelitis) model research.
→ Browse MOG antibodies & proteins

NfL (Neurofilament Light Chain) — Serum NfL is the leading pharmacodynamic biomarker in MS clinical trials, reflecting acute axonal damage and treatment response. Anti-NfL antibodies enable ultrasensitive immunoassay platforms for disease activity monitoring.

GFAP — Serum GFAP is an emerging biomarker for astrocytic damage in progressive MS. Anti-GFAP antibodies support reactive astrogliosis quantification and progressive MS stratification studies.
→ Browse GFAP antibodies

References

1. Filippi M, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. DOI

2. Hauser SL, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. DOI

3. Barro C, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200052. DOI

4. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89-102. DOI